The first participant has received a dose in a study that will examine the pharmacokinetics (PK) and safety of the therapy in pregnant women at risk for HPA-1a alloimmunization, which can cause FNAIT.

The single-arm, dose confirmation trial aims to assess RLYB212's pharmacokinetics (PK) and safety in pregnant women who are at a higher risk for human platelet antigen (HPA) 1a alloimmunisation ...